2型糖尿病患者血清Betatrophin水平与骨密度的相关性研究

目的探讨2型糖尿病(type 2 diabetes mellitus,T2DM)患者血清Betatrophin水平与骨密度(bone mineral density,BMD)的相关性。方法选择95例T2DM患者,采用双能X线骨密度仪检测所有患者腰椎1～4(L1-L4)、股骨颈(femoral neck,FN)及全髋(total hip,TH)部位BMD,按BMD将患者分为骨量正常组(n=46)及骨量异常组(包括骨量减少及骨质疏松,n=49)。所有患者均行口服葡萄糖耐量试验(oral glucose tolerance test,OGTT)及胰岛素释放试验。血清Betatrophin水平用酶联免疫吸附法进行检测。结果与BMD正常组相比,BMD异常组血清Betatrophin水平显著增高(P0.05)。相关分析显示,Betatrophin与FN、TH两个部位骨密度呈负相关(r=-0.238、-0.208,P均0.05)。根据血清Betatrophin水平由低到高分为3组,BMD异常在3组中的发生率逐渐升高(38.7%、53.1%及62.5%)。结论 T2DM骨密度异常患者血清Betatrophin水平显著升高,提示Betatrophin可能在糖尿病骨质疏松症的发生发展中发挥作用,对该指标进行检测可为糖尿病骨质疏松症的预防和治疗提供新的临床依据。

Study of the relationship between bone mineral density and betatrophin levels in patients with type 2 diabetes mellitus

Objective To investigate the relationship between bone mineral density (BMD) and betatrophin in patients with type 2 diabetes mellitus (T2DM). Methods We enrolled 95 patients with T2DM. BMD of the lumbar vertebrae (L1-L4), femoral neck (FN), and total hip (TH) in all the patients were measured using dual energy x-ray absorptiometry. According to BMD values, subjects were divided into normal bone mass group (n=46) and abnormal bone mass group (including low bone mass and osteoporosis, n=49). Oral glucose tolerance test (OGTT) and insulin releasing test were conducted in all the patients. Serum betatrophin levels were determined with ELISA method. Results Compared with normal bone mass group, the levels of serum betatrophin in abnormal bone mass group was significantly elevated (P<0.05). Based on the correlation analysis, the levels of serum betatrophin was negatively correlated with BMD of FN and TH (r =-0.238, -0.208, respectively, all P<0.05). When subjects were divided into three subgroups from low to high betatrophin levels, there was an increase in abnormal BMD rates (38.7%, 53.1% and 62.5%). Conclusion Serum betatrophin could be an indicator in the occurrence and development of osteoporosis in patients with type 2 diabetes mellitus.